<DOC>
	<DOCNO>NCT01968655</DOCNO>
	<brief_summary>To provide emergency access OBI-1 patient Acquired Hemophilia serious bleed episode access active clinical study site associate OBI-1-301 study .</brief_summary>
	<brief_title>Expanded Access B-Domain Deleted Recombinant Porcine Factor VIII ( OBI-1 ) Treatment Acquired Hemophilia A Due Factor VIII Inhibitory Auto-antibodies</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Autoantibodies</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Written inform consent participant legal representative . Participants acquire hemophilia autoimmune inhibitor human factor VIII . Has serious bleed episode , document investigator . Be willing able follow instruction attend study visit . Participants take antithrombotics may include depend time elapse since take medication . Life expectancy least 90 day prior onset bleed episode . Hemodynamically unstable blood transfusion , fluid resuscitation pharmacologic volume replacement pressor therapy . Has establish reason bleed correctable . Bleeding episode assess likely resolve leave untreated . AntiOBI1 inhibitor exceed 20 BU ( prospectively retrospectively ) . Subsequent bleeding episode site initial qualify bleeding episode within 2 week follow final OBI1 dose initial qualify bleeding episode , subsequent bleeding episode different site initial qualify bleeding episode within 1 week follow final OBI1 dose initial qualify bleeding episode consider `` new '' qualify bleed episode . Prior history bleed disorder acquire hemophilia . Known major sensitivity ( anaphylactoid reaction ) pig hamster product . Use hemophilia medication within 3 6 ( depend medication ) hour prior OBI1 administration . Participation clinical study within 30 day first OBI 1 treatment . Anticipated need treatment device study may interfere evaluation . Abnormal baseline finding Inability unwillingness comply study design , protocol requirement , followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Factor VIII Inhibitory Auto-antibodies</keyword>
</DOC>